X
Xencor, Inc. (XNCR)
NGM – Real vaqt narxi. Valyuta: USD
12.44
-0.35 (-2.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
12.44
-0.35 (-2.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Xencor, Inc., klinik bosqichdagi biofarmatsevtika kompaniyasi, saraton va otoimmün kasalliklarni davolash uchun muhandislik qilingan antitelalarni kashf qilish va ishlab chiqishga qaratilgan. Kompaniya atipik gemolitik uremik sindrom, generalizatsiyalangan miyasteniya gravis va nevromiyelit optik spektr buzilishi bilan og'rigan bemorlarni davolash uchun Ultomirisni; va takroriy yoki refrakter diffuz katta B-hujayrali limfomani davolash uchun Monjuvi'ni taqdim etadi. Shuningdek, u buyrak hujayrasi karsinomasini davolash uchun bispesifik antitelasi XmAb819; tuxumdon saratonini davolash uchun I faza bosqichida bo'lgan XmAb541; keng tarqalgan o'simta antigeniga bog'lanadigan bispesifik antitelasi XmAb808; Kron kasalligi va yarali kolit bilan og'rigan bemorlar uchun klinik rivojlanish bosqichida bo'lgan XmAb942; revmatoid artritni davolash uchun Ib faza tadqiqotida bo'lgan bispesifik T-hujayrasi Plamotamab; va idiopatik yallig'lanishli miopatiyalar bilan og'rigan bemorlar uchun XmAb657 ni ishlab chiqadi. Bundan tashqari, kompaniya prostata saratonini davolaydigan bispesifik T-hujayrali yengil vosita Xaluritamig; oshqozon, oshqozon-song'iz va oshqozon osti bezi saratonini davolash uchun ASP2138; metastatik kastratsiyaga chidamli prostata saratonini davolash uchun JNJ-9401; otoimmün kasalliklari bo'lgan bemorlarni davolash uchun antitel Obexelimab; surunkali gepatit Delta davosi Tobevibart; paroksismal tungi gemoglobinuriya va boshqa alternativ yo'nalishlardagi buzilishlarni davolash uchun Zaltenibart; inson immunitet tanqisligi virusini davolash uchun Teropavimab va zinlirvimab; XmAb Fc texnologiyalaridan foydalanadigan antitel dori nomzodi Novartis; va B-hujayrali malignansiyalarni davolash uchun JNJ-1493 ni ishlab chiqadi. Kompaniya 1997 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Pasadena shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bassil I. Dahiyat Ph.D. | Co-Founder, CEO, President & Director |
| Dr. John R. Desjarlais Ph.D. | Executive VP of Research & Chief Scientific Officer |
| Dr. Mark Osterman M.D. | Senior Vice President of Clinical Development (Autoimmune) |
| Mr. Bart Jan Cornelissen | Senior VP & CFO |
| Mr. Charles Liles | Associate Director and Head of Corporate Communications & Investor Relations |
| Mr. Dane Vincent Leone C.F.A. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 10-Q | xncr-20260331.htm |
| 2026-05-05 | 8-K | xncr-20260504.htm |
| 2026-04-27 | DEFA14A | xencorincdefa14a-2026.htm |
| 2026-04-27 | ARS | a2025ars.pdf |
| 2026-03-09 | 8-K | xncr-20260304.htm |
| 2026-03-04 | 8-K | xncr-20260304.htm |
| 2026-02-25 | S-3ASR | xencor-sx3asr2026.htm |
| 2026-02-25 | 10-K | xncr-20251231.htm |
| 2026-01-08 | 8-K | xncr-20260108.htm |
| 2025-11-05 | 10-Q | xncr-20250930.htm |
| Executive VP & Chief Strategy Officer |
| Mr. Eric P. Kowack | Senior Vice President of Program Leadership & Alliance Management |
| Mr. Kirk Rosemark RAC | Senior Vice President of Regulatory Affairs & Quality Assurance |
| Ms. Celia E. Eckert J.D. | Senior VP, General Counsel & Corporate Secretary |
| Ms. Jennifer Sandoz | Senior VIce President of Human Resources |